Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR2 | Q92731 | 19/20 | 0.90 |
| ▸ | ESR1 | P03372 | 16/20 | 0.90 |
| ▸ | ESRRA | P11474 | 1/20 | 0.50 |
| ▸ | HCAR1 | Q9BXC0 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5127319 | 0.95 | ESR2 (1.00) | ESR2ESR1 | |
| SCHEMBL5121211 | 0.85 | ESR2 (0.67) | ESR2ESR1HCAR1 | |
| SCHEMBL14013176 | 0.85 | ESR2 (0.67) | ESR2ESR1HCAR1 | |
| SCHEMBL14013209 | 0.84 | ESR2 (0.65) | ESR2ESR1HCAR1 | |
| SCHEMBL14013197 | 0.84 | ESR2 (0.65) | ESR2ESR1HCAR1 | |
| SCHEMBL14013181 | 0.83 | ESR2 (0.64) | ESR2ESR1HCAR1 | |
| SCHEMBL14013194 | 0.83 | ESR2 (0.69) | ESR2ESR1HCAR1 | |
| SCHEMBL14013192 | 0.83 | ESR2 (0.65) | ESR2ESR1HCAR1 | |
| SCHEMBL14013202 | 0.82 | ESR2 (0.62) | ESR2ESR1ESRRAHCAR1 | |
| SCHEMBL5112791 | 0.81 | ESR2 (0.65) | ESR2ESR1HCAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7456188-B1 | C-5 substituted quinazolinone derivatives as selective estrogen receptor beta modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-11-25 | — | — | US | disclosed |
| US-7456188-B1 | C-5 substituted quinazolinone derivatives as selective estrogen receptor beta modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-11-25 | — | — | US | disclosed |
| US-7381730-B2 | 3-arylquinazoline derivatives as selective estrogen receptor beta modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-06-03 | — | — | US | disclosed |
| US-7381730-B2 | 3-arylquinazoline derivatives as selective estrogen receptor beta modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-06-03 | — | — | US | disclosed |
| US-7381730-B2 | 3-arylquinazoline derivatives as selective estrogen receptor beta modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-06-03 | — | — | US | disclosed |
| US-20030220227-A1 | 3-Arylquinazoline derivatives as selective estrogen receptor beta modulators | BRISTOL-MYERS SQUIBB COMPANY | 2003-11-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030220227-A1 | 3-Arylquinazoline derivatives as selective estrogen receptor beta modulators | ESR2, ESRRA, ESRRG | ESR2 1/4885ESR1 9/4885ESRRA 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.